Sarepta Therapeutics Income Statement - Quarterly (NASDAQ:SRPT)

Add to My Stocks
$29.68 $0.51 (1.69%) SRPT stock closing price Mar 23, 2017 (Closing)

Looking at financial statements, along with the Sarepta Therapeutics stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis.   The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. Like any other income statement, the SRPT income statement also itemizes revenue, operating expenses, and profits for a quarter or year and reflects a QoQ revenue growth of $5.42M when compared to the same period in the past. One also needs to look at Sarepta Therapeutics assets, operating expenses and Sarepta Therapeutics free cash flow. The profit and loss statement shows revenue of $5.42M for 2016-Q4. Revenue has grown by $5.42M QoQ for SRPT stock. View details of revenue and profits for Sarepta Therapeutics for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Sarepta Therapeutics Net Sales or Revenues
5.42M---1.25M---0.03M1.06M
Cost Of Goods Sold (COGS)----------
Sarepta Therapeutics Gross Profit
----1.25M---0.04M1.05M
Research & Development Expense70.75M34.34M-38.82M41.38M36.67M29.18M39.16M30.84M21.85M
Selling General & Admin Expense22.94M22.18M-20.87M24.34M15.09M12.92M22.69M13.92M12.88M
Income Before Depreciation Depletion Amortization-93.69M-56.53M--59.7M-64.46M-51.76M-42.1M-61.86M-44.72M-33.67M
Depreciation Depletion Amortization----------
Non Operating Income-0.06M-0.2M--0.06M-0.23M-0.17M0.25M0.3M0.31M4.44M
Interest Expense----------
Sarepta Therapeutics Pretax Income
-88.45M-56.74M--59.77M-64.7M-51.93M-41.85M-61.55M-44.42M-29.22M
Provision for Income Taxes----------
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-88.45M-56.74M-62.3M-59.77M-64.68M-51.94M-41.85M-61.56M-44.42M-29.23M
Extraordinary Items & Discontinued Operations----------
Sarepta Therapeutics Net Income (Profit/Loss)
-88.45M-56.74M-62.3M-59.77M-64.68M-51.94M-41.85M-61.56M-44.42M-29.23M
Average Shares used to compute Diluted EPS54.62M48.25M46.16M45.7M44.88M41.57M41.36M41.32M41.3M41.07M
Average Shares used to compute Basic EPS54.62M48.25M46.16M45.7M44.88M41.57M41.36M41.32M41.3M41.07M
Income Before Nonrecurring Items-86.31M-52.8M-61.68M-59.77M-64.68M-51.94M-41.85M-61.56M-44.41M-33.48M
Income from Nonrecurring Items-2.14M-3.94M-0.63M------4.26M
Sarepta Therapeutics Earnings Per Share Basic Net
-1.65-1.18-1.35-1.31-1.44-1.25-1.01-1.49-1.08-0.71
Sarepta Therapeutics Earnings Per Share Diluted Net
-1.65-1.18-1.35-1.31-1.44-1.25-1.01-1.49-1.08-0.71
EPS Diluted Before Nonrecurring Items-1.58-1.10-1.34-1.31-1.44-1.25-1.01-1.49-1.08-0.81
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Income statement for another ticker

1:11
SRPT
The key things to look for in an income statement while doing Sarepta Therapeutics stock analysis are:
  • Revenue: This is the inflow that is generated from the sale of goods or services and is $5.42M for this quarter of 2016-Q4. Our Sarepta Therapeutics revenue chart gives a clear visual representation of how the topline growth has been. Investors often invest in only those companies where the revenue is growing at a steady rate.
  • Bottom line: Most businesses like Sarepta Therapeutics try to improve their bottom line by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.
The income statement is also called statement of revenue and expense. The financials along with Sarepta Therapeutics historical stock prices provides a lot of details about the firm. .